Company Overview
DexCom delivered impressive Q4 2025 earnings on February 13th—about three weeks ago—reporting revenue of $1.21 billion (up 22% year-over-year) and earnings per share of $0.62 that exceeded analyst expectations. The continuous glucose monitoring (CGM) pioneer has successfully expanded beyond its core Type 1 diabetes market into Type 2 diabetes and even non-diabetic health-conscious consumers through its new Stelo over-the-counter product.
What makes DexCom particularly compelling right now is the Stelo launch success revealed during the February 13th earnings call. CEO Kevin Sayer disclosed that Stelo—the first FDA-cleared over-the-counter CGM that doesn’t require a prescription—generated over $200 million in Q4 revenue just months after its September 2025 launch. The product is being adopted by Type 2 diabetics who don’t use insulin (a 30+ million person market in the U.S. alone) as well as athletes and biohackers tracking metabolic health. Management projected Stelo could reach $1+ billion in annual revenue by late 2026 as awareness builds and distribution expands beyond direct-to-consumer into retail pharmacy channels.
Key Technical and Fundamental Drivers
Strong Q4 Beat → February 13th Results
DexCom reported Q4 2025 results three weeks ago showing $1.21B revenue (up 22% YoY), $0.62 EPS (beating estimates), with strength across prescription and OTC products.
Stelo OTC Success → $200M+ Quarterly Revenue
The over-the-counter Stelo CGM generated over $200 million in Q4 revenue just months after September 2025 launch, with management projecting $1B+ annual run rate by late 2026.
International Expansion → 25% Growth
International revenue grew 25% year-over-year as DexCom expands into European and Asian markets where CGM adoption is still in early stages compared to the U.S.
G7 Upgrade Cycle → Installed Base Conversion
The G7 sensor (30% smaller, more accurate, 12-hour warmup vs 2 hours) is driving upgrades from older G6 users, with 80%+ of new patients choosing G7.
Market Expansion → 100M+ Addressable
DexCom’s addressable market has expanded from 8 million insulin-dependent diabetics to 100+ million including Type 2 non-insulin users and wellness consumers.
Market Takeaway
DexCom’s February 13th earnings—three weeks old—represent a major inflection point as the company transitions from a medical device serving a narrow diabetic population to a mainstream health monitoring platform. The Stelo over-the-counter launch generating $200+ million quarterly after just a few months validates that demand for continuous glucose monitoring extends far beyond insulin-dependent diabetics. Type 2 diabetics who manage their condition through diet and oral medications represent a 30+ million person U.S. market that previously had limited access to CGM technology due to prescription requirements and insurance hurdles.
The wellness/biohacking angle adds another dimension—athletes, fitness enthusiasts, and health-conscious consumers are increasingly using CGMs to understand how different foods affect their glucose levels and optimize metabolic health. At $99 for a two-week sensor (direct-to-consumer pricing), Stelo is accessible to mainstream consumers in a way prescription CGMs costing $300+ per month never were. The G7 sensor technology providing the foundation for both prescription and OTC products demonstrates DexCom’s innovation leadership, with the device being 30% smaller and significantly more accurate than competing CGMs from Abbott and Medtronic. International markets growing 25% provide additional runway as European and Asian healthcare systems begin reimbursing CGMs more broadly. With the addressable market expanding from 8 million to 100+ million potential users and Stelo just beginning its growth trajectory, DexCom offers exposure to the convergence of medical devices and consumer wellness—a rare combination of healthcare defensiveness with consumer growth potential.